Eli Lilly Signs a License Agreement with Seed Therapeutics for Protein Degradation-Based Therapies
Shots:
- Seed Therapeutics to receive $10M upfront- $10M equity investment- ~$780M as pre/clinical development- regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration
- Seed utilizes molecular glue protein degradation technology to develop potential new therapies
- The agreement allows Seed to advance its platform to deliver new molecules targeting proteins that cause human diseases
Ref: Globe Newswire | Image: Eli Lilly
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com